四川德阳地区丙型肝炎病毒基因型分布特征

肝脏 ›› 2020, Vol. 25 ›› Issue (12): 1306-1308.

四川德阳地区丙型肝炎病毒基因型分布特征

陈学兵, 欧世梅, 刘建英, 刘舒舒, 王秀

618000 四川德阳市人民医院感染科(陈学兵,刘建英,刘舒舒),耳鼻咽喉科(欧世梅),生殖遗传科(王秀)

收稿日期:2020-03-01 出版日期:2020-12-31 发布日期:2021-02-26
通讯作者: 欧世梅,Email:gszxm@163.com

Distribution of hepatitis C virus genotypes in Deyang area Sichuan province

CHEN Xue-bing¹, OU Shi-mei², LIU Jian-ying¹, LIU Shu-shu¹, WANG Xiu³

1. Department of Infectious Diseases, People's Hospital of Deyang City, Sichuan 618000, China;
2. Department of Otolaryngology, People's Hospital of Deyang City, Sichuan 618000, China;
3. Department of Reproductive Genetics, People's Hospital of Deyang City, Sichuan 618000, China

Received:2020-03-01 Online:2020-12-31 Published:2021-02-26
Contact: OU shi-mei,Email:gszxm@163.com

摘要/Abstract

摘要： 目的分析四川德阳地区丙型肝炎病毒基因型的分型情况,为本地区的疾病防控提供参考。方法收集2013年1月到2019年7月在德阳市人民医院门诊及住院的丙型病毒性肝炎患者的基本资料及血清,采用RT-PCR荧光探针扩增技术进行病毒基因分型,进行统计分析。结果共有821例丙型病毒性肝炎患者纳入本研究。共检测出7种基因型及其亚型,分别为1b、2a、3a、3b、6a、1b+3b和2a+3b,其中1b型占到全部基因型的92.08%,有14例未能获得基因分型结果。男女性患者在各基因型之间的构成比均无统计学意义(P>0.05)。年龄≤40岁的患者中,基因3a、3b和6a型的比例明显高于年龄>40岁的患者,而基因1b型低于年龄>40岁的患者,差异均有统计学意义(P<0.05)。2019年基因1b型的患者比例高于以往几年同型的患者(P<0.05)。结论四川德阳地区丙型肝炎病毒基因1b型占绝对优势,基因3型和6型在年轻人中更为常见。

关键词: 丙型病毒性肝炎, HCV, 基因型, 分布特征

Abstract: Objective To study the genotypes and subtypes of hepatitis C virus (HCV) patients in Deyang area.Methods The baseline data and serum of patients infected with HCV in out hospital from January 2013 to July 2019 were collected. Viral genotyping was performed by reverse transcription-PCR fluorescent probe amplification technique. Chi-square test was used for data analysis.Results A total of 821 patients with HCV infection were included in this study. There were 7 genotypes and different subtypes including 1b, 2a, 3a, 3b, 6a, 1b+3b and 2a+3b among these patients, of which 1b accounted for 92.08% of all genotypes. There was no significant difference in the composition ratio between male and female patients between the genotypes (P>0.05). Among patients aged 40 years or younger, the proportions of genotypes 3a, 3b and 6a were significantly higher than those of patients older than 40 years, while the proportion of genotype 1b was lower than that of patients older than 40 years (P<0.05).Conclusion The major genotype of HCV in Deyang area is 1b. Genotypes 3 and 6 are more common in patients aged 40 years or younger.

Key words: Hepatitis C, Hepatitis C virus, Gene type, Distribution

陈学兵, 欧世梅, 刘建英, 刘舒舒, 王秀. 四川德阳地区丙型肝炎病毒基因型分布特征[J]. 肝脏, 2020, 25(12): 1306-1308.

CHEN Xue-bing, OU Shi-mei, LIU Jian-ying, LIU Shu-shu, WANG Xiu. Distribution of hepatitis C virus genotypes in Deyang area Sichuan province[J]. Chinese Hepatolgy, 2020, 25(12): 1306-1308.

参考文献

[1] Chen Y, Yu C, Yin X, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect,2017,6:e95.
[2] 中华医学会肝病学分会,中华医学会感染病学分会. 《丙型肝炎防治指南》(2015年更新版). 实用肝脏病杂志,2016,19:521-538.
[3] 苏迎盈,刘慧鑫,汪宁. 中国丙型肝炎病毒基因型分布. 中华流行病学杂, 2013,34:80-84.
[4] 肖桂荣,徐珽. 2009～2013年四川大学华西医院1998株丙型肝炎病毒基因分型研究. 四川大学学报(医学版),2016,47:755-758.
[5] European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol, 2014,60:392-420.
[6] Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology,2011,54:1433-1444.
[7] El-Shamy A, Shoji I, Kim SR, et al. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One, 2012,7:e30513.
[8] Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 2002,347:975-982.
[9] Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut,2006,55:1350-1359.
[10] Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med Wkly,2010,140:3-11.
[11] D'Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol, 2019,70:379-387.
[12] Boerekamps A, Vanwolleghem T, van der Valk M, et al. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). J Hepatol, 2019,70:554-557.
[13] Fu Y, Wang Y, Xia W, et al. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J Viral Hepat, 2011,18:42-52.
[14] 聂滨,张开炯,刘靳波,等. 中国丙型肝炎病毒基因型分布回顾及Meta分析. 检验医学与临床,2016,13:2879-2881.

[1]	张军建, 张矿召. 丙型肝炎病毒NS3非结构蛋白对人胚胎肝细胞L02细胞增殖以及端粒酶活性的研究[J]. 肝脏, 2020, 25(2): 135-137.
[2]	林瑞, 陈竹, 陈艳, 王丽, 陈雄. 四川地区乙型肝炎病毒基因分型与耐药突变分析[J]. 肝脏, 2020, 25(11): 1165-1167.
[3]	王彩红, 卓志强, 黄冰清, 唐文涛, 谢新宝. Citrin缺陷病6例临床特征及基因型特点[J]. 肝脏, 2020, 25(11): 1223-1226.
[4]	纪林秀, 吴亚, 王蜀强, 杨兴祥. 四川省丙型肝炎患者HCV基因分型及基线HCV NS5A耐药突变位点分析[J]. 肝脏, 2019, 24(8): 917-918.
[5]	王丽, 陈竹, 曾义岚, 吴蓓, 周觅, 朱丽, 胡朝霞. 四川地区丙型肝炎病毒基因型分布特点[J]. 肝脏, 2019, 24(4): 450-451.
[6]	刁青. DAA治疗在肝硬化患者中的应用效果[J]. 肝脏, 2019, 24(3): 256-258.
[7]	徐鹤翔, 郑吉顺, 解俊侠, 李明远, 章媛媛, 梁利民. 合肥地区丙型肝炎病毒基因分型分布特征[J]. 肝脏, 2019, 24(1): 81-83.
[8]	张瑞芹, 陈延平, 冯继红. 陕北地区乙型肝炎病毒基因型分布特征以及变化规律[J]. 肝脏, 2018, 23(9): 802-803.
[9]	蒋莹莹, 卞丹丹, 周海洋, 段淑丽, 王钊, 刘霜, 陈煜, 郑素军, 段钟平. 慢性丙型肝炎患者睡眠现状调查[J]. 肝脏, 2018, 23(4): 302-304.
[10]	钱小娟. Glecaprevir-Pibrentasvir联合疗法治疗基因3型HCV感染疗效评估[J]. 肝脏, 2018, 23(12): 1087-1089.
[11]	鲍丽静, 焦志云, 蔡炜, 刘克伟. 直接作用抗病毒药物的抗丙型肝炎病毒作用及对患者血清血管内皮生长因子水平的影响[J]. 肝脏, 2018, 23(10): 919-921.
[12]	倪俊明, 丁艳, 张红梅, 王建芳. 丙型肝炎病毒母婴垂直传播的概率及影响因素[J]. 肝脏, 2018, 23(10): 922-924.
[13]	陈芳洁, 王秀敏. 丙型肝炎患者治疗期间HCV RNA含量变化及其与血清ALT、前白蛋白、总胆红素的相关性研究[J]. 肝脏, 2017, 22(9): 827-830.
[14]	李积杰,保成兰,尕玛才培,王赟,李微,周彬,王战会,李华. 乙型肝炎病毒 C/D重组体毒株的三种鉴定方法[J]. 肝脏, 2017, 22(8): 695-699.
[15]	甘志超, 赵冰红, 刘莹, 黄前川. 不同基因型丙型肝炎患者脂肪性肝病发生率及血糖血脂水平差异[J]. 肝脏, 2016, 21(9): 763-765.